Basak, M., Sharif, O., Lord, S. E., Borodovsky, J. T., Marsch, L. A., Springer, S. A., Nunes, E. V., Brackett, C. D., Archibald, L. J., & Preum, S. M. (2025). Information Needs for Opioid Use Disorder Treatment Using Buprenorphine Product: Qualitative Analysis of Suboxone-Focused Reddit Data. Journal of Medical Internet Research, 27, e68886. https://doi.org/10.2196/68886

Seval, N., Roth, P., Frank, C. A., Di Paola, A., Litwin, A. H., Vander Wyk, B., Neirinckx, V., Schlossberg, E., Lawson, P., Strong, M., Schade, M. A., Nunez, J., Levin, F. R., Brady, K. T., Nunes, E. V., & Springer, S. A. (2025). Initiating Injectable Buprenorphine in People Hospitalized With Infections. JAMA Network Open, 8(5), e2513000. https://doi.org/10.1001/jamanetworkopen.2025.13000

Silva, M. D., & Linn, K. Z. (2025). Successful Initiation of Buprenorphine for Chronic Non-Cancer Pain in an Opioid-Experienced Patient: A Case Report. Journal of Pain & Palliative Care Pharmacotherapy, 39(2), 244–247. https://doi.org/10.1080/15360288.2025.2459169

Shulman, M., Choo, T.-H., Ohrtman, K., Pavlicova, M., Rotrosen, J., & Nunes, E. V. (2025). Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial. Drug and Alcohol Dependence, 268, 112550. https://doi.org/10.1016/j.drugalcdep.2025.112550

Balise, R. R., Hu, M.-C., Calderon, A. R., Odom, G. J., Brandt, L., Luo, S. X., & Feaster, D. J. (2024). Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder. PLOS ONE, 19(11), e0312695. https://doi.org/10.1371/journal.pone.0312695

Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., & Rudolph, K. E. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open, 7(10), e2436612. https://doi.org/10.1001/jamanetworkopen.2024.36612

Williams, A. R., Mauro, C. M., Chiodo, L., Huber, B., Cruz, A., Crystal, S., Samples, H., Nowels, M., Wilson, A., Friedmann, P. D., Remien, R. H., & Olfson, M. (2024). Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug and Alcohol Dependence, 263, 112389. https://doi.org/10.1016/j.drugalcdep.2024.112389

Nunes, E. V., Comer, S. D., Lofwall, M. R., Walsh, S. L., Peterson, S., Tiberg, F., Hjelmstrom, P., & Budilovsky-Kelley, N. R. (2024). Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use. JAMA Network Open, 7(6), e2417377. https://doi.org/10.1001/jamanetworkopen.2024.17377

Williams, A. R., Mauro, C. M., Huber, B., Chiodo, L., Crystal, S., Samples, H., & Olfson, M. (2024). Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement. American Journal of Psychiatry, 181(5), 457–459. https://doi.org/10.1176/appi.ajp.20230808

Shulman, M., Provost, S., Ohrtman, K., Novo, P., Meyers-Ohki, S., Van Veldhuisen, P., Oden, N., Otterstatter, M., Bailey, G. L., Liu, D., Rotrosen, J., Nunes, E. V., & Weiss, R. D. (2024). Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemporary Clinical Trials, 142, 107543. https://doi.org/10.1016/j.cct.2024.107543

Xu, K. Y., Gertner, A. K., Greenfield, S. F., Williams, A. R., & Grucza, R. A. (2024). Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims. Addiction Science & Clinical Practice, 19(1). https://doi.org/10.1186/s13722-024-00450-0

Cerdá, M., Hamilton, A. D., Hyder, A., Rutherford, C., Bobashev, G., Epstein, J. M., Hatna, E., Krawczyk, N., El-Bassel, N., Feaster, D. J., & Keyes, K. M. (2024). Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties. Epidemiology, 35(3), 418–429. https://doi.org/10.1097/ede.0000000000001703

O’Grady, M. A., Elkington, K. S., Robson, G., Achebe, I. Y., Williams, A. R., Cohall, A. T., Cohall, R., Christofferson, M., Garcia, A., Ramsey, K. S., Lincourt, P., & Tross, S. (2024). Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators. Substance Abuse Treatment, Prevention, and Policy, 19(1). https://doi.org/10.1186/s13011-024-00593-y

Luo, S. X., Feaster, D. J., Liu, Y., Balise, R. R., Hu, M.-C., Bouzoubaa, L., Odom, G. J., Brandt, L., Pan, Y., Hser, Y.-I., VanVeldhuisen, P., Castillo, F., Calderon, A. R., Rotrosen, J., Saxon, A. J., Weiss, R. D., Wall, M., & Nunes, E. V. (2024). Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry, 81(1), 45. https://doi.org/10.1001/jamapsychiatry.2023.3596

French, R., Lyons, E., Schachter, A., Treston, J. A., Marshall, A., Lattimer, J., Bisaga, A., Behar, E., & Aronowitz, S. V. (2023). “Because of this rotation, this is what I want to do”: Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students. Journal of the American Association of Nurse Practitioners, 35(12), 826–834. https://doi.org/10.1097/jxx.0000000000000949

Gopaldas, M., Wenzel, K., Campbell, A. N. C., Jalali, A., Fishman, M., Rotrosen, J., Nunes, E. V., & Murphy, S. M. (2023). Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. Psychiatric Services, 74(12), 1227–1233. https://doi.org/10.1176/appi.ps.20220549

Hsu, M., Jung, O. S., Kwan, L. T., Jegede, O., Martin, B., Malhotra, A., & Suzuki, J. (2024). Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets. Journal of Substance Use and Addiction Treatment, 157, 209216. https://doi.org/10.1016/j.josat.2023.209216

Perry, A., Wheeler-Martin, K., Hasin, D. S., Terlizzi, K., Mannes, Z. L., Jent, V., Townsend, T. N., Pamplin, J. R., Crystal, S., Martins, S. S., Cerdá, M., & Krawczyk, N. (2023). Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic. Drug and Alcohol Dependence, 253, 111023. https://doi.org/10.1016/j.drugalcdep.2023.111023

Mariani, J. J., Dobbins, R. L., Heath, A., Gray, F., & Hassman, H. (2023). Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. The American Journal on Addictions, 33(1), 8–14. Portico. https://doi.org/10.1111/ajad.13484

Seval, N., Nunez, J., Roth, P., Schade, M., Strong, M., Frank, C. A., Litwin, A. H., Levin, F. R., Brady, K. T., Nunes, E. V., & Springer, S. A. (2023). Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal of Addiction Medicine, 17(4), e232–e239. https://doi.org/10.1097/adm.0000000000001136

Tofighi, B., Badiei, B., Badolato, R., Lewis, C. F., Nunes, E., Thomas, A., & Lee, J. D. (2023). Integrating Text Messaging in a Low Threshold Telebuprenorphine Program for New York City Residents with Opioid Use Disorder during COVID-19: A Pilot Randomized Controlled Trial. Journal of Addiction Medicine, 17(5), e281–e286. https://doi.org/10.1097/adm.0000000000001161

Samples, H., Nowels, M. A., Williams, A. R., Olfson, M., & Crystal, S. (2023). Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. American Journal of Preventive Medicine, 65(1), 19–29. https://doi.org/10.1016/j.amepre.2023.01.037

Tardelli, V., Xu, K. Y., Bisaga, A., Levin, F. R., Fidalgo, T. M., & Grucza, R. A. (2023). Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk. BMJ Mental Health, 26(1), e300728. https://doi.org/10.1136/bmjment-2023-300728

Williams, A. R., Mauro, C. M., Feng, T., Wilson, A., Cruz, A., Olfson, M., Crystal, S., Samples, H., & Chiodo, L. (2023). Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention. American Journal of Psychiatry, 180(6), 454–457. https://doi.org/10.1176/appi.ajp.20220456

Greiner, M. G., Shulman, M., Opara, O., Potter, K., Voronca, D. C., Tafessu, H. M., Hefner, K., Hamilton, A., Scheele, C., Ho, R., Dresser, L., Jelstrom, E., Fishman, M., Ghitza, U. E., Rotrosen, J., Nunes, E. V., & Bisaga, A. (2023). Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study. Contemporary Clinical Trials, 128, 107148. https://doi.org/10.1016/j.cct.2023.107148

Brandt, L., Hu, M.-C., Liu, Y., Castillo, F., Odom, G. J., Balise, R. R., Feaster, D. J., Nunes, E. V., & Luo, S. X. (2023). Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. American Journal of Psychiatry, 180(5), 386–394. https://doi.org/10.1176/appi.ajp.20220312

Ronan, K., Hughes Driscoll, C. A., Decker, E., Gopalakrishnan, M., & El Metwally, D. (2023). Resource utilization and convalescent care cost in neonatal opioid withdrawal syndrome. Journal of Neonatal-Perinatal Medicine, 16(1), 49–57. https://doi.org/10.3233/npm-221060

Daniulaityte, R., Nahhas, R. W., Silverstein, S., Martins, S., & Carlson, R. G. (2023). Trajectories of non–prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis. Journal of Substance Use and Addiction Treatment, 147, 208973. https://doi.org/10.1016/j.josat.2023.208973

Williams, A. R., Aronowitz, S. V., Rowe, C., Gallagher, R., Behar, E., & Bisaga, A. (2023). Telehealth for opioid use disorder: retention as a function of demographics and rurality. The American Journal of Drug and Alcohol Abuse, 49(2), 260–265. https://doi.org/10.1080/00952990.2023.2180382

Castillo, F., Scalise, D., Hernandez, D., Gupta, R., Basaraba, C. N., Corbeil, T., Comer, S. D., & Schneeberger, A. R. (2022). Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City. Journal of Addictive Diseases, 41(1), 91–97. https://doi.org/10.1080/10550887.2022.2067463

Luba, R., Martinez, S., Jones, J., Pravetoni, M., & Comer, S. D. (2023). Immunotherapeutic strategies for treating opioid use disorder and overdose. Expert Opinion on Investigational Drugs, 32(1), 77–87. https://doi.org/10.1080/13543784.2023.2173062

Kiluk, B. D., Kleykamp, B. A., Comer, S. D., Griffiths, R. R., Huhn, A. S., Johnson, M. W., Kampman, K. M., Pravetoni, M., Preston, K. L., Vandrey, R., Bergeria, C. L., Bogenschutz, M. P., Brown, R. T., Dunn, K. E., Dworkin, R. H., Finan, P. H., Hendricks, P. S., Houtsmuller, E. J., Kosten, T. R., … Strain, E. C. (2023). Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder. JAMA Psychiatry, 80(1), 84. https://doi.org/10.1001/jamapsychiatry.2022.4020

Hirchak, K. A., Amiri, S., Kordas, G., Oluwoye, O., Lyons, A. J., Bajet, K., Hahn, J. A., McDonell, M. G., Campbell, A. N. C., & Venner, K. (2022). Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes. Substance Abuse Treatment, Prevention, and Policy, 17(1). https://doi.org/10.1186/s13011-022-00457-3

Williams, A. R., Johnson, K. A., Thomas, C. P., Reif, S., Socías, M. E., Henry, B. F., Neighbors, C., Gordon, A. J., Horgan, C., Nosyk, B., Drexler, K., Krawczyk, N., Gonsalves, G. S., Hadland, S. E., Stein, B. D., Fishman, M., Kelley, A. T., Pincus, H. A., & Olfson, M. (2022). Commentary Article: Opioid use Disorder Cascade of Care Framework Design: A Roadmap. Substance Abuse, 43(1), 1207–1214. https://doi.org/10.1080/08897077.2022.2074604

Williams, A. R. (2022). Commentary on Burns et al: MOUD saves lives, especially after 60 days, and the longer the better. Addiction, 117(12), 3089–3090. Portico. https://doi.org/10.1111/add.16043

Petrakis, I., Springer, S. A., Davis, C., Ralevski, E., Gu, L., Lew, R., Hermos, J., Nuite, M., Gordon, A. J., Kosten, T. R., Nunes, E. V., Rosenheck, R., Saxon, A. J., Swift, R., Goldberg, A., Ringer, R., & Ferguson, R. (2022). Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice, 17(1). https://doi.org/10.1186/s13722-022-00286-6

Maricich, Y. A., Nunes, E. V., Campbell, A. N. C., Botbyl, J. D., & Luderer, H. F. (2022). Safety and Efficacy of a Digital Therapeutic for Substance use Disorder: Secondary Analysis of Data from a NIDA Clinical Trials Network Study. Substance Abuse, 43(1), 937–942. https://doi.org/10.1080/08897077.2022.2060425

Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K. M., Jones, C. M., & Cerdá, M. (2022). Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019”. International Journal of Drug Policy, 110, 103786. https://doi.org/10.1016/j.drugpo.2022.103786

Shulman, M., Hu, M. C., Nunes, E. V., & Bisaga, A. (2022). Initiating Long-acting Injectable Naltrexone: Procedure for a Second Attempt After a First Attempt Fails. Journal of Addiction Medicine, 16(5), 588–591. https://doi.org/10.1097/adm.0000000000000974

Sung, M. L., Black, A. C., Blevins, D., Henry, B. F., Cates-Wessel, K., Dawes, M. A., Drexler, K., Hagle, H., Molfenter, T., Levin, F. R., Becker, W. C., & Edelman, E. J. (2022). Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. Journal of Addiction Medicine, 16(5), 505–513. https://doi.org/10.1097/adm.0000000000000948

Foltin, R. W., Zale, S., Sykes, K. A., Nagaraj, N., Scranton, R. E., & Comer, S. D. (2022). A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys. Drug and Alcohol Dependence, 239, 109599. https://doi.org/10.1016/j.drugalcdep.2022.109599

Rudolph, K. E., Williams, N. T., Goodwin, A. T. S., Shulman, M., Fishman, M., Díaz, I., Luo, S., Rotrosen, J., & Nunes, E. V. (2022). Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug and Alcohol Dependence, 239, 109609. https://doi.org/10.1016/j.drugalcdep.2022.109609

Paschen-Wolff, M. M., Velasquez, R., Aydinoglo, N., & Campbell, A. N. C. (2022). Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States. Journal of Substance Abuse Treatment, 140, 108828. https://doi.org/10.1016/j.jsat.2022.108828

Greiner, M. G., Shulman, M., Scodes, J., Choo, T.-H., Pavlicova, M., Opara, O., Campbell, A. N. C., Novo, P., Fishman, M., Lee, J. D., Rotrosen, J., & Nunes, E. V. (2022). Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone. Substance Use & Misuse, 57(11), 1732–1742. https://doi.org/10.1080/10826084.2022.2112230

Williams, A. R., Mauro, C. M., Feng, T., Wilson, A., Cruz, A., Olfson, M., Crystal, S., Samples, H., & Chiodo, L. (2022). Non–prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder. Journal of Substance Abuse Treatment, 139, 108770. https://doi.org/10.1016/j.jsat.2022.108770

Samples, H., Williams, A. R., Crystal, S., & Olfson, M. (2022). Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. Journal of Substance Abuse Treatment, 139, 108774. https://doi.org/10.1016/j.jsat.2022.108774

Tsui, J. I., Campbell, A. N. C., Pavlicova, M., Choo, T.-H., Lee, J. D., Cook, R. R., Shulman, M., Nunes, E. V., & Rotrosen, J. (2022). Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug and Alcohol Dependence, 236, 109469. https://doi.org/10.1016/j.drugalcdep.2022.109469

Nesoff, E. D., Marziali, M. E., & Martins, S. S. (2021). The estimated impact of state‐level support for expanded delivery of substance use disorder treatment during the COVID‐19 pandemic. Addiction, 117(6), 1781–1786. Portico. https://doi.org/10.1111/add.15778

Mintz, C. M., Xu, K. Y., Presnall, N. J., Hartz, S. M., Levin, F. R., Scherrer, J. F., Bierut, L. J., & Grucza, R. A. (2022). Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder. JAMA Network Open, 5(5), e2211634. https://doi.org/10.1001/jamanetworkopen.2022.11634